VolitionRx Limited (NYSE American: VNRX) has announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study, which achieved 97% specificity and identified 86% of lymphoma cases, marks a significant step forward in the development of a blood-based liquid biopsy test for feline cancer.
The company stated that this technology addresses a substantial unmet need in veterinary medicine. Companion animals, particularly cats, are often diagnosed with cancer at advanced stages due to a lack of non-invasive screening tools. A simple blood test could enable earlier detection, potentially improving treatment outcomes and quality of life for affected animals. This represents not only a medical advancement but also a commercial opportunity for VolitionRx as it expands its presence in the growing companion animal oncology market.
VolitionRx noted that the publication of this study in a peer-reviewed journal is expected to unlock a $5 million contractual milestone payment from a partner. This payment would provide additional funding to support further development and commercialization efforts. The company is working toward product commercialization of the Nu.Q Vet prototype, with potential future revenue generation from sales and royalties.
The implications of this announcement extend beyond VolitionRx. The companion animal diagnostics market is expanding rapidly as pet owners increasingly seek advanced medical care for their animals. A reliable, non-invasive blood test for feline cancer could set a new standard in veterinary oncology, potentially leading to earlier interventions and better prognoses. Moreover, the success of this approach in cats could pave the way for similar tests in other companion animals, such as dogs, further broadening the market.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it develops and commercializes simple, cost-effective blood tests to detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more information, visit the company's website at www.Volition.com.
The full press release can be viewed at https://ibn.fm/ARsEY.
